Ally Financial Inc. acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 18,000 shares of the medical research company’s stock, valued at approximately $2,632,000.
Several other large investors have also recently made changes to their positions in AMGN. FMR LLC increased its stake in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock worth $5,963,875,000 after buying an additional 4,144,154 shares in the last quarter. Asset Management One Co. Ltd. increased its position in Amgen by 426.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,331,811 shares of the medical research company’s stock worth $194,885,000 after buying an additional 1,078,691 shares during the period. State Street Corp increased its position in Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock worth $5,016,268,000 after buying an additional 919,966 shares during the period. Russell Investments Group Ltd. bought a new position in Amgen during the fourth quarter worth approximately $117,903,000. Finally, Morgan Stanley increased its position in Amgen by 8.0% in the third quarter. Morgan Stanley now owns 8,678,786 shares of the medical research company’s stock worth $1,447,708,000 after buying an additional 639,410 shares during the period. 79.04% of the stock is currently owned by institutional investors.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at 169.24 on Tuesday. The firm has a market cap of $124.64 billion, a PE ratio of 16.53 and a beta of 1.15. Amgen, Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a 50 day moving average of $171.88 and a 200 day moving average of $159.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.10. The business earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The business’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.61 earnings per share. Equities research analysts anticipate that Amgen, Inc. will post $12.31 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be paid a $1.15 dividend. The ex-dividend date is Monday, May 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.72%. Amgen’s dividend payout ratio (DPR) is presently 44.92%.
Your IP Address:
AMGN has been the topic of a number of recent analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $165.00 target price on shares of Amgen in a research report on Friday. Cann reaffirmed an “outperform” rating on shares of Amgen in a research report on Wednesday, February 22nd. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research report on Tuesday, March 14th. Bank of America Corp raised shares of Amgen from a “neutral” rating to a “buy” rating and increased their target price for the company from $156.68 to $192.00 in a research report on Wednesday, February 1st. Finally, Royal Bank of Canada set a $190.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Wednesday, January 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $187.41.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024681/ally-financial-inc-buys-shares-of-18000-amgen-inc-amgn.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.